You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 255 No. 12, March 28, 1986 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL INVESTIGATION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Predicting the Predisposition to Osteoporosis

Gonadotropin-Releasing Hormone Antagonist for Acute Estrogen Deficiency Test

Rafat Abbasi, MD; Gary D. Hodgen, PhD

JAMA. 1986;255(12):1600-1604.


Abstract

A reliable predictive test to identify perimenopausal women who are vulnerable to the adverse effects of severe estrogen deficiency may be useful in deciding for whom and when to begin estrogen replacement therapy. Primate models were employed to determine (1) whether short-term treatment with gonadotropin-releasing hormone antagonist allows prospective identification of individuals at greatest risk for a negative calcium balance during overt estrogen deficiency; (2) whether high-dose clomiphene citrate is sufficiently estrogenic to abate urinary calcium loss and to sustain vaginal and perineal tissues after ovariectomy; and (3) whether clomiphene citrate will provide these beneficial estrogenic effects without inducing endometrial proliferation and menstruation after progestin withdrawal. The data indicate the capability of short-term gonadotropin-releasing hormone-antagonist test to identify individuals likely to lose calcium rapidly after ovariectomy. This result has potential usefulness in the prediction of susceptibility to osteoporosis after medical castration or spontaneous menopause. At high doses, clomiphene citrate therapy was nearly as effective as high-dose conjugated equine estrogens for conservation of urinary calcium, yet clomiphene citrate did not cause endometrial proliferation or withdrawal bleeding after progesterone therapy.

(JAMA 1986;255:1600-1604)



Author Affiliations

From the Department of Obstetrics and Gynecology, Columbia Hospital for Women, Georgetown University Medical Center, Washington, DC (Dr Abbasi); the Pregnancy Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md (Dr Hodgen); and the Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Va (Dr Hodgen).


Footnotes

Read in part before the American Fertility Society, Chicago, Oct 1, 1985.

Reprint requests to the Jones Institute for Reproductive Medicine, Lewis Hall, Room 2011, Eastern Virginia Medical School, Norfolk, VA 23507 (Dr Hodgen).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Estrogen Withdrawal Syndrome
Yen
JAMA 1986;255:1614-1615.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.